Stem cell clinic biotech Stemedica has just been sued by one of its own board members based on allegations related to money the company raised, according to CourtHouseNews. The actual suit, filed by an investment company Tiara Holdings and board member Anthony Marlon, can be read here. CourtHouseNews writes: “Tiara Holdings II LLC sued Stemedica Cell […]
Stemedica sued by board member over alleged mishandling of funds Read More »
For me it’s been a wild week of grant and paper writing, grant review, going over data, and more, but finally I had a chance to watch this week’s Dr. Oz show on stem cell clinics in full last night and I give it an A+ grade. A show producer went undercover with an MS patient to a
Kudos to Dr. Oz for stellar stem cell clinic show: time for more action Read More »
In the whirlwind that is the stem cell and regenerative medicine world, there are many concerning things that need attention, but also good stuff happens too and this post focuses on the positive. The Asterias spinal cord injury clinical trial, a phase 1/2a trial called SCiStar, continues to make encouraging news with a clean safety profile
Good stem cell news on trials, FDA, cool new papers & more Read More »
Patient advocate Ted Harada is the recipient of this year’s Stem Cell Person of the Year Award. Congrats also to the runner-up, HD patient advocate Judy Roberson. The three of us together are pictured at left. You can read about the 20 nominees here and see the vote results that picked the 10 finalists here.
Stem Cell Person of the Year 2016: Patient Advocate Ted Harada Read More »
What are the latest developments in stem cells and regenerative medicine in this first week of 2017 and right before the end of the past year? Here are some of the headlines and papers that have popped up that seem notable or surprising. Be sure to also check out our stem cell & regenerative medicine
TGIF: Week’s Stem Cell Headlines, Papers, & Resources Read More »
Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions,
Grading my stem cell predictions for 2016: how’d I do? Read More »
Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How
Asterias interview: stem cell spinal cord injury trials advance Read More »
I received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks. I’ve started an on-line vote where you can vote once per day for
20 Nominees for Stem Cell Person of the Year 2016 Award Read More »
The 21st Century Cures Act has some important provisions that would impact the stem cell and regenerative medicine field. What is driving these efforts is a widespread sense that the status quo of regenerative medicine oversight isn’t working very well. I’m talking with key stakeholders and still trying to sort out my thoughts on the
Perspectives on Cures Act stem cell provisions possible benefits & risks Read More »
The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to
REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises Read More »